⌘K
t
Sareum Holdings PLC will announce its unaudited financial results for the six months ended 31 December 2025 on Thursday, 12 March 2026. The Company will also host a live presentation for investors and potential shareholders on the same date at 14:00 GMT via the Investor Meet Company platform.
| Date | 3 Mar 2026 |
| Time | 07:00:09 |
| Category | Results |
| ID | 0060V |
Sareum Holdings PLC
("Sareum" or the "Company")
Notice of Interim Results for the Year Ended 31 December 2025 and Investor Presentation
Cambridge, UK, 3 March 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, will announce its unaudited financial results for the six months ended 31 December 2025 on Thursday, 12 March 2026.
The Company will also be holding a live presentation to investors on Thursday, 12 March 2026 at 14:00 GMT via the Investor Meet Company platform.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 11 March 2026, 09:00 GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.
A copy of the presentation will be made available on the Company's website following the presentation.
- Ends -
For further information:
|
Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
Singer Capital Markets (Joint Corporate Broker) Phil Davies
|
020 7409 3494
020 7496 3000
|
|
Oberon Capital (Joint Corporate Broker) Mike Seabrook / Nick Lovering
|
020 3179 5300 |
|
ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi |
020 3709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for certain haematological cancers and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease
The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com